1,479
Views
21
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Asthma and COPD in Alpha-1 Antitrypsin Deficiency. Evidence for the Dutch Hypothesis

Pages 366-374 | Published online: 20 Sep 2010

REFERENCES

  • ATS/ERS Statement: Standards for the Diagnosis and Management of Individuals with alpha-1 Antitrypsin Deficiency, Lung disease section, Am J Respir Crit Care Med 2002; 168: 823–849.
  • Silverman EK, Sandhaus RA, Alpha-1 antitrypsin deficiency. N Engl J Med 2009; 360:2749–57.
  • Orie NGM, Sluiter HJ, De Vries K, Tammeling GJ et al. the host factor in bronchitis. In: Orie NGM, Sluiter HJ editors. Bronchitis. Assen, The Netherlands: Royal Van Gorcum; 1961. Pp 43–59.
  • Laurell CB and Erikssson S. the electrophoretic alpha-1-globulin pattern in alpha-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963;15: 132–40.
  • Fabbri LM, Romagnoli M, Corbetta L, Casori G, Busletic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418–424.
  • Makino S, Chosy L Valdivia E emphysema with hereditary alpha1 antitrypsin deficiency masquerading as asthma. J Allergy 1970; 46: 40–48.
  • Niggeman B, Albani M. Bronchial asthma and homozygous alpha1 antitrypsin deficiency (PiZZ) in three members of a family (in German) Klin Pediatr 1989; 201:412–41.
  • Tobin MJ, Cook PJL, Hutchison DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects for feature Pi type Z; a survey by the British thoracic association. Br J Dis Chest 1983; 77:14–27.
  • M. Prados, F.J. Monteseirin, M.I. Carranco, A. Aragon R Conde and J. Conde, Phenotypes of alpha-1 antitrypsin in intrinsic asthma and ASA-triad patients, Allergol Immunopathol Madr 1995; 23: 24–28.
  • R. Dodge, M.G. Cline and B. Burrows, Comparisons of asthma, emphysema and chronic bronchitis diagnoses in a general population sample, Am Rev Respir Dis 1986; 133: 981–986.
  • Eden E, J. Hammel, F.N. Rouhani, M.L. Brantly, A.F. Barker and S. Buist , Asthma features in severe alpha-1 antitrypsin deficiency. Experience of the NHLBI Registry, Chest 2003; 123: 765–771.
  • Eden E, Strange C, Holladay B, Xie Lianqi. Asthma and allergy in alpha-1 antitrypsin deficiency. Respiratory Medicine 2006; 100: 1384–1391.
  • DeMeo DL, Sandhaus RA, Barker AF, Brantly M, Eden E, McElvaney NG, Rennard S, Determinants of airflow obstruction in severe alpha1-antitrypsin deficiency. Thorax 2007; 62: 806–813.
  • Piitulainen E, Sveger T, Respiratory symptoms and lung function in young adults with severe alpha-1 antitrypsin deficiency (PiZZ). Thorax; 2002; 57: 705–708.
  • Colp CR, Talavera W, Goldman D, Green J, Multz A, Lieberman J. Profile of bronchospastic disease in Puerto Rican patients in New York City. A possible relationship to alpha-1 antitrypsin variants. Arch Int Med 1990; 150: 2349–54.
  • Townley RG, Southard JG, Radford P, Hopp RJ, Bewtra AK, Ford L. Association of MS Pi phenotype with airway hyperresponsiveness. Chest 1990, 8: 594–599.
  • Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha1-antitrypsin deficiency in poorly controlled asthma – Results from the ALA-ACRC low dose theophylline trial. Journal of Asthma 2007; 44: 605–608
  • van Veen IH, ten Brinke A, Van Der Linden AC, Rabe KF, Bel EH. Deficient alpha-1 antitrypsin phenotypes and persistent airflow limitation in severe asthma. Respiratory Med 2006; 100: 1534–39.
  • von Ehrenstein OS, Maier EM, Weiland SK, Carr D, Hirsch T Roscher AA, von Mutius E. Alpha1-antitrypsin and the prevalence and severity of asthma. Arch Dis Child 2004; 89: 230–231.
  • Montealegre F, Delgado A, Toro a, Vargas W, Chardon D, Bayona M, Campbell E. Alfa 1 antitrypsin and protease levels in Puerto Rican asthmatics: a pilot study. P.R Health Sci J 2006; 25: 117–25.
  • Miravitlles M, Vila S, Torrella M, Balcells E, Rodriguez-Frias F, De La Roza C, Jardi R, Vidal R. Influence of deficient alpha1 antitrypsin phenotypes on characteristics and severity of asthma in adults. Resp Med 2002; 96: 186–92.
  • Wadsworth MEJ, Vinall IE, Jones AL, Hardy RJ, Whitehouse DB, Butterworth SL, Hilder WS, Lovegrove JU, Swallow DM. Alpha1-antitrypsin as a risk for infant and adult respiratory outcomes in a national birth cohort. Am J Cell Mol Biol 2004; 31: 559–564.
  • Sigsgaard T, Brundskund I, Omland O, Hjort C, Lund ED, Pedersen OF, Miller MR. S and Z alpha1-antitrypsin alleles are risk factors for bronchial hyperresponsiveness in young farmers: an example of gene environment interaction. Eur Resp J 2000; 16: 50–55.
  • Sigsgaard T, Brandslund I, Lund E, Rasmussen JB, Varming H. Low normal alpha 1- antitrypsin concentrations and MZ phenotype are associated with byssinosis and familial allergy in cotton mill workers. Pharmacogenetics 1994; 4: 135–141.
  • Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in the diagnosis of alpha-1 antitrypsin deficiency. A continuing problem. Chest 2005; 128: 1989–1994.
  • Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha1-antitrypsin deficiency: results of a survey, Cleveland Clin J Med 1994; 61: 461–467.
  • Anthonisen NR, Wright EC and the IPPB Trial Group, Chronic obstructive pulmonary disease, Am Rev Respir Dis 1986; 133: 814–819.
  • Vignola AM, Bonanno A, Profita M, Scichilone N, Spatafora M, Bosquest J, Bonsignora G, Bellia V. Effect of age and asthma duration upon elastase and alpha1-antitrypsin levels in adult asthmatics. Eur Respir J 2003;22: 795–801.
  • Forteza R, Botvinnikova A, Ahmed A, Cortes A, Gundel H, Wanner A, Abraham WM. The interaction of alpha1-proteinase inhibitor and tissue kallikrein in controlling allergic ovine airway hyperresponsiveness. Am J Respir Crit Care Med 1996; 154:36–42.
  • Scuri M, Botvinnikova Y, Lauredo IT, Abraham WM. Recombinant alpha1-proteinase inhibitor blocks antigen and mediator induced airway responses on sheep. J Appl Physiol 2002; 93:1900–1906.
  • Gelfand EW, Dakhama A. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy and Clin Immunol 2006: 117; 577–82.
  • Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of COPD in patients with alpha (1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999; 160:1968–75
  • Hubbard R C, Fells A, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha1 antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991; 88: 891–897.
  • Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Resp Crit Care Med 2002; 165: 1494–149.
  • Gaillard MC, Kilroe-Smith TA, Hogheira C, Dunn D Jenkins T, Fine B, Kallenback J. Alpha1 protease inhibitor in bronchial asthma: phenotypes and biochemical characteristics. Am Rev Respir Dis 1992; 145:1311–1315.
  • Malerba M, Radaeli A, Ceriani L, Tantucci C, Grassi V. Airway hyperresponsiveness in a large group of subjects with alpha1-antitrypsin deficiency: a cross sectional controlled study. J Int Med 2003: 253; 351–358.
  • Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. The lung health study. Airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145;300–310.
  • Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15 year follow up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194–1200.
  • Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Jianfeng Xu MS, Panhuysen CI, Meyers DA, Levitt DA. Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995; 333: 894–900.
  • Gottleib DJ, Sparrow D, O’Connor GT, Weiss CT. Skin test reactivity to common aeroallergens and decline in lung function. The normative aging study. Am J Respir Crit Care Med 1996; 153: 561–6.
  • Eden E, Mitchell D, Mehlman B, Khouli H, Nejat M, Grieco MH , Atopy, asthma and emphysema in patients with severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 1997; 156;68–74.
  • DeMeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Strange C, Turino G, Silverman EK. IL10 Polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol 2008; 38: 114–120
  • Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Starnge C, Turino GM, Sandhaus RA, Griggith JL, Silverman EK. Development of predictive models for airflow obstruction in alpha-1 antitrypsin deficiency. Am J Epidemiol 2009; 17:1005–1013.
  • Dowson LJ, Guest PJ, Stockley RA., Longitudinal changes in physiological, radiological and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001; 164: 1805–1809.
  • Hospers JJ, Schouten JP, Weiss ST, Rijcken B, Postma DS, Asthma attacks with eosinophilia predict mortality from COPD in a general population sample. Am J Respir Crit Care Med 1999; 160: 1869–1874.
  • Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE, for the Lung Health Study Research Group. Bronchodilator response in the Lung Health Study over 11 years. Eur Respir J 2005; 26: 45–51.
  • Silverstein MD, Reed CF, O’Connell EJ, Melton LJ, O’Fallon WM, Yunginger JW. Long-term survival of a cohort of community residents with asthma. N Engl J Med 1994; 331: 1537–41.
  • Ulrik C.S, Lange P. Decline of lung function in adults with bronchial asthma, Am J Respir Crit Care Med 1994; 150: 629–634.
  • Silva G.E, Sherrill D.L, Guerra S, Barbee R.A. Asthma as a risk factor for COPD in a longitudinal study, Chest 2004; 126: 59–65.
  • O’Byrne PM, Pederson S, Lamm CJ, Tan WC, Busse WW and the START investigators. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179: 19–24.
  • Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009; 32: 1338–1344
  • Campos MA, Alezemi S Zhang G, Salathe M, Wanner A, Sandhaus RA, Baier H. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009; 135: 600–608
  • The Alpha-1 Antitrypsin Deficiency Study Group, Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin, Am J Respir Crit Care Med 1998; 158: 49–59.
  • Dirksen A, Dijkman JH, Madsen F et al. A randomized control trial of alpha-1 antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468–1472
  • Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485
  • Barker AF, Siemsen F, Pasley D, D’Silva R, Buist AS. Replacement therapy for alpha-1 antitrypsin deficiency. A program for long term administration. Chest 1994; 105: 1406–10.
  • Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, Sandhaus RA. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir Med 2009; 103: 1532–9.
  • Dirksen A, Pittulainen E, Parr DG exploring the role of CT densitometry: a randomized study of augmentation in alpha 1 antitrypsin deficiency. Eur Respir J 2009; 33:1345–1353.
  • Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006, 61: 93–4
  • de Marco R, Marcon A, Jarvis D J Allergy Clin Immunol Inhaled steroids are associated with reduced lung function decline in subjects with asthma and elevated total IgE. 2007 119 611–7.
  • den Otter JJ, van Schayck CP, Folgering HT, Van Den Boom G, Akkermans RP, van Weel C. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme. Eur J Gen Pract 2007; 13:89–91.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.